| |
October 16-18, 2023 | Boston, MA
|
|
Today's Big NewsJul 20, 2023 |
| By James Waldron Despite interest from GSK and high hopes of leading the next generation of influenza A prophylaxis, Vir Biotechnology’s monoclonal antibody has failed its first phase 2 challenge. |
|
|
|
| Philadelphia, PA |  |
|
|
By Max Bayer Johnson & Johnson's reassessment of its infectious disease and vaccine work does not appear to be over, with the company cutting the number of assets in development in half. The cuts come six months after the overhaul of the two units was first disclosed to staff. |
By James Waldron With Pfizer’s entry in the RSV race soaking up most of the press attention, it’s easy to forget that the Big Pharma has other vaccines in the works. They include a maternal vaccine for group B streptococcus (GBS), which has posted some positive data after a long period of radio silence. |
Sponsored by Altasciences Optimize Your Drug Development Timeline With This Dosage Form Can you name five benefits of using liquid-filled, hard-shell capsules in drug development over other solid oral dosage forms? Find out! |
|
BioIVT not only provides an unparalleled selection of hepatocytes, microsomes, rCYPs and other control and disease state biospecimens, but also experts to guide you to the right solution. View Biospecimens >> 
|
|
By Gabrielle Masson Sanofi is paying Recludix Pharma $125 million and offering up more than $1.2 billion in biobucks for a pact that will take aim at multiple immunological and inflammatory indications. |
By James Waldron Five months after waving goodbye to its phase-2-ready depression drug candidate and laying off 55% of staff, Eliem Therapeutics is closing its sole remaining program and assessing its “strategic alternatives.” |
By Gabrielle Masson GSK has returned an investigational Shigella vaccine to LimmaTech Biologics as the Swiss biotech brings on a former CureVac exec as CEO. |
By James Waldron While Ipsen’s troubled rare disease candidate was given a second chance by the FDA, the regulator’s European equivalents haven’t been as sympathetic. |
By Max Bayer FibroGen's previously announced cost-cutting plans are taking shape, with the biotech announcing layoffs affecting 32% of its team. Arch-backed ImmuneID is also laying off staff to help push a lead asset into the clinic. |
By Zoey Becker The 13 updated principals proposed by the FTC and the DOJ point to tougher merger reviews. This comes as the FTC scrutinizes two blockbuster biopharma mergers. |
By Colleen DeGuzman, Kaiser Health News Tucked into the hundreds of pages of legislative language to reauthorize the Federal Aviation Administration is a provision to change the life-or-death process by which human organs are flown commercially from donor to recipient. |
By Ben Adams Despite the major decline in COVID-19 vaccine sales since the 2022 peak, the infectious disease market is still expected to grow by 5.7% through 2029 with Pfizer, Gilead and GSK all set to be the dominant forces in this market. |
By Andrea Park For the quarter, Abbott’s COVID-19 tests brought in just $263 million. Not only does that mark a drop of nearly 90% compared to the $2.3 billion the diagnostics raked in during the same period last year, but it also dampens the company’s overall sales performance, which came in 11.4% lower than last year. |
By Frank Diamond Recent and undocumented immigrants face barriers to postpartum care that could turn treatable conditions into serious health risks, according to a JAMA Network study. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines. |
|
|---|
|
|
|
Tuesday, July 25, 2023 1pm ET / 10am PT New methods in scalable compute cloud environments not only accelerate drug discovery in a cost-effective manner, but benefit from reduced deployment time, accelerated GPU speed, and reduced infrastructure costs. Register now to learn more. 
|
|
Whitepaper Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
